Atlanta and Carlsbad, Calif. – September 20, 2026 -- Field Medical, Inc. reported 12-month outcomes from its first-in-human Field PULSE trial showing 94.2% per-vein durability for pulmonary vein isolation using an optimized waveform, with results published in JACC: Clinical Electrophysiology and presented as a Late-Breaking Clinical Trial at HRX Live 2026.
Subsecond ablation cuts median procedure time to 13 minutes
The trial recorded a 13-minute median elapsed pulmonary vein isolation (PVI) ablation time, with a fastest case completed in 7.7 minutes. Field Medical's high-voltage focal pulsed field ablation (PFA) architecture, delivered through its FieldForce PFA System, applies energy in under 200 milliseconds per point, reducing the need for prolonged catheter stability during atrial procedures.
No primary safety events reported across the cohort
The study recorded no primary safety events. At 12 months, 80% of patients treated with the optimized waveform were free from atrial arrhythmias, and 49% received non-pulmonary-vein ablation for additional atrial targets, indicating flexibility beyond standard PVI protocols.
Atrial data extend evidence base built on ventricular trial results
Field PULSE builds on Field Medical's earlier peer-reviewed work in ventricular tachycardia. Six-month outcomes from the company's VCAS trial were published in Circulation in 2025. The new atrial data apply the same high-voltage focal PFA architecture through a distinct point-by-point workflow in a different cardiac substrate.
Vivek Reddy, M.D., co-principal investigator and electrophysiologist at Mount Sinai Health System, said delivering the full ablation application in under 200 milliseconds reduces the need for prolonged catheter stability while preserving the flexibility of point-by-point ablation.
CEO frames results as evidence for a dual-substrate PFA platform
Mark A. Turco, M.D., president and CEO of Field Medical, said the FieldForce platform was designed to address focal ablation challenges beginning in the ventricle, and that Field PULSE demonstrates the same architecture supports an instantaneous ablation workflow in the atrium. The study, titled "High-Voltage Focal PFA Catheter for 'Instant' Point-By-Point Ablation: The First-In-Human FIELD-PULSE Trial to Treat AF," carries DOI 10.1016/j.jacep.2026.09.001.
The FieldForce PFA System remains an investigational device, limited under U.S. federal law to investigational use. Field Medical received Breakthrough Device Designation and entry into the FDA TAP Pilot Program for its ventricular tachycardia indication in 2024.